Galectin Therapeutics Inc. GALT
Regular-session close
After hours · Nov 19, 4:01 PM ET
- YTD
- -32.45%
- 1 year
- -51.05%
5D -0.39 (-12.19%)
- Market cap
- 283.46M
- EPS (ttm)
- -0.32
- Shares out
- 62.76M
- Forward P/E
- -0.53
- YTD return
- -32.45%
- 1-year return
- -51.05%
- 50-day average
- 2.51
- 200-day average
- 2.64
- Volume
- 220.46K
- Avg volume
- 252.46K
- Open
- 2.99
- Previous close
- 2.98
- Day's range
- 2.78 – 2.99
- 52-week range
- 2.03 – 7.13
- Beta
- 0.63
- Price target
- 11.00 (+291.5%)
Key statistics
- Enterprise value
- 241.35M
- Free cash flow
- -20.36M
- Total cash
- 25.60M
- Total debt
- 93.47M
- Short % of float
- 18.41%
Fundamental scorecard
2 of 25 checks passed on GALT’s reported financials
2of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.20 | -0.18 | +0.02 | +10.00% |
| Aug 13, 2024 | Jun 1, 2024 | -0.16 | -0.20 | -0.04 | -25.00% |
| May 15, 2024 | Mar 1, 2024 | -0.16 | -0.19 | -0.03 | -18.75% |
| Mar 29, 2024 | Dec 1, 2023 | -0.16 | -0.16 | 0.00 | 0.00% |
| Nov 13, 2023 | Sep 1, 2023 | -0.16 | -0.24 | -0.08 | -50.00% |
| Aug 14, 2023 | Jun 1, 2023 | -0.21 | -0.15 | +0.06 | +28.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 17, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- galectintherapeutics.com
News
Galectin Therapeutics (GALT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
All You Need to Know About Galectin Therapeutics (GALT) Rating Upgrade to Buy
Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update Galectin Therapeutics Q3 EPS $(0.04) Beats $(0.05) Estimate
Your note
Sign in to keep a note on GALT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CZIRR JAMES C | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 22, 2024 | 0 |
| ELDRED KARY N. | Director | Purchase | Oct 22, 2024 | 54,638 |
| FREEMAN KEVIN D | Director | Purchase | Oct 16, 2024 | 132,832 |
| LEWIS JOEL | Chief Executive Officer | Purchase | Apr 23, 2024 | 0 |
| UIHLEIN RICHARD E | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jan 23, 2024 | 10,296,500 |
| ZORDANI RICHARD A. JR | Director | Purchase | Aug 22, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.40% | 2,134,205 | 1.90M | Sep 29, 2024 |
| Blackrock Inc. | 2.56% | 1,607,124 | 1.43M | Sep 29, 2024 |
| Osaic Holdings Inc | 1.88% | 1,182,095 | 1.05M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.37% | 862,542 | 767.75K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.77% | 483,264 | 430.15K | Sep 29, 2024 |
| Wealthspire Advisors, LLC | 0.63% | 398,374 | 354.59K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.99% | 1,247,562 | 1.11M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.07% | 670,160 | 596.51K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.59% | 372,101 | 331.21K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 278,527 | 247.92K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.32% | 198,844 | 176.99K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.17% | 107,352 | 95.55K | Oct 30, 2024 |
